has function has role vaccinated in route immunizes against disease immunizes recipient leukemia Homo sapiens subcutaneous route therapeutic vaccine function vaccine in clinical trial role leukemia cancer vaccine therapeutic cancer vaccine whole cell cancer vaccine GM-K562 cell vaccine NCT: https://clinicaltrials.gov/study/NCT00809250 NCT: https://clinicaltrials.gov/study/NCT00301093 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6293 A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome. Gene name: GM-CSF cancer vaccine NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190 NCT: https://clinicaltrials.gov/study/NCT00442130 6293 Jie Zheng Hayleigh Kahn 1437 NCT: https://clinicaltrials.gov/study/NCT00361296